Genetron Health and AstraZeneca Signed a Strategic Cooperation Agreement to Jointly Promote the Development of Precision Medicine

Release time:2019-03-08

On March 7, Genetron Health officially signed a Strategic Cooperation Agreement with AstraZeneca, the world's leading biopharmaceutical company. In the future, the two sides will carry out in-depth cooperation around precision medicine. Min Yin, General Manager of Oncology Division, AstraZeneca China, and Sizhen Wang, CEO of Genetron Health, delivered speeches and witnessed the signing ceremony.


Genetron Health and AstraZeneca Signed a Strategic Cooperation Agreement to Jointly Promote the Development of Precision Medicine

Genetron Health and AstraZeneca Signed a Strategic Cooperation Agreement to Jointly Promote the Development of Precision Medicine


This strategic cooperation will start with BRCA testing and will give full play to the advantages of both parties and promote mutual benefit leveraging their respective strengths, thus benefiting patients, improving cancer diagnosis and treatment in China, and promoting the development of precision medicine.


As a company with international certificates CAP/CLIA, the BRCA gene detection service provided by Genetron Health uses a new high-throughput sequencing platform to detect the 50 coding exons sequences of BRCA1 and BRCA2 genes and 16,000 bases on both sides. The mutation, insertion, and deletion of information of each base are analyzed, covering 100% of the regions with possible genetic variation. Leveraging the BRCA testing technology, Genetron Health is fast progressing on the cooperation with the Chinese Academy of Medical Sciences Cancer Hospital/National Cancer Center in the field of breast cancer data, and building a large breast cancer database in China.


Previously, in the field of other cancers’ testing and LDT service, Genetron Health has participated in AstraZeneca's lung cancer digital PCR and NGS quality evaluation program and achieved excellent results.


Min Yin, General Manager of AstraZeneca Oncology Division, said: 'Genetron Health is an excellent company in the field of genetic testing, and it attaches great importance to standardized treatment and testing. We are very much looking forward to long-term cooperation with such excellent companies to build a community of common destiny based on the principle of equality, mutual benefit and mutual trust.'


Genetron Health and AstraZeneca Signed a Strategic Cooperation Agreement to Jointly Promote the Development of Precision Medicine


Sizhen Wang, CEO of Genetron Health, said: 'Genetron Health has been constantly pursuing higher quality standards and providing reliable results for doctors and patients. In last year's 'NGS BRCA Calibration Program', Genetron Health passed with high scores. The launch of strategic cooperation today will become the starting point for Genetron Health and AstraZeneca cooperation in the field of multi-cancer and multi-gene detection. We also look forward to cooperating with AstraZeneca in clinical testing and data mining to exploit the value of genetic testing in multiple fields, enabling precision medicine to benefit more patients and the society as a whole.'


In recent years, Genetron Health has fully utilized its expertise in cancer gene detection, focusing on synergy with the upstream and downstream enterprises and has cooperated with companies such as Thermo Fisher, Illumina, EditGene, and Juventas Bio. This strategic cooperation with AstraZeneca has started a new chapter in the cooperation between Genetron Health and pharmaceutical companies.


In the future, Genetron Health will continue to use their comprehensive strength in cancer genomics to intensively research in cancer precision medicine, continue to explore the secret of life and load the power of fight against cancer.


About AstraZeneca China


Since its entry in China in 1993, AstraZeneca has prioritized science and innovation to meet China's growing medical needs and striving to realize the ambition of “Innovating to benefit patients and becoming a trusted medical partner in China”. AstraZeneca's China headquarter is located in Shanghai and has more than 10,000 employees nationwide. In 2017, sales in China reached $2.96 billion and invests more than 750 million US dollars in China, has 2 production bases in Wuxi and Taizhou, and establishes a logistics center in Wuxi. In China, AstraZeneca's focus is on areas most urgently needed by Chinese patients, including cardiovascular and metabolic diseases, cancer, respiratory and digestive disease and anesthesia.


COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
犀牛云提供云计算服务
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Verification code:
Genetron Health Genetron Health Management